EGFR

Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control

Retrieved on: 
화요일, 4월 9, 2024
Epigenomics, EGFR, NSCLC, Patient, DNA, Messenger, Lung cancer, Therapy, MYC

Validation of novel translational assay enables detection and quantification of site-specific DNA methylation from liquid biopsies to assess target engagement of OTX-2002, our lead clinical-stage epigenomic controller

Key Points: 
  • Validation of novel translational assay enables detection and quantification of site-specific DNA methylation from liquid biopsies to assess target engagement of OTX-2002, our lead clinical-stage epigenomic controller
    CAMBRIDGE, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the presentation of new preclinical data demonstrating the anti-tumor effect of a MYC-targeting epigenomic controller (MYC-EC) in models of EGFR inhibitor (EGFRi)-resistant non-small cell lung cancer (NSCLC) at the American Association for Cancer Research Annual Meeting 2024, taking place in San Diego, California, April 5 – 10.
  • The Company also presented preclinical data validating a novel pharmacodynamic biomarker assay for monitoring on-target engagement and activity of its clinical-stage EC candidate, OTX-2002.
  • “We’re excited to share these preclinical data at this year’s AACR Annual Meeting, which continue to validate Omega’s platform,” said Thomas McCauley, Ph.D., Chief Scientific Officer of Omega Therapeutics.
  • “These results further underscore the tremendous potential for a MYC-directed epigenomic controller as a novel orthogonal treatment strategy for non-small cell lung cancer as a monotherapy and in combination with existing therapies.

Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines

Retrieved on: 
월요일, 4월 8, 2024
EGFR, Patient, Anaplastic lymphoma kinase, Research, Alectinib, Active ingredient, Lung cancer, AACR, AstraZeneca, ALK, Vaccine

Fort Lee, NJ, April 08, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) today recapped poster highlights from the 2024 American Association for Cancer Research (AACR) conference demonstrating highly synergistic antiproliferative activity in epidermal growth factor receptor (EGFR)-resistant non-small cell lung cancer (NSCLC) cells of NXP900 in combination with osimertinib, the active ingredient in TagrissoTM, an EGFR inhibitor approved for the treatment of NSCLC. The data reported, which confirms data previously published by the research team at Astra Zeneca, demonstrated that the combination reverses resistance to osimertinib versus osimertinib alone.

Key Points: 
  • The data reported, which confirms data previously published by the research team at Astra Zeneca, demonstrated that the combination reverses resistance to osimertinib versus osimertinib alone.
  • In addition, NXP900 demonstrated potent, single agent, antiproliferative activity in anaplastic lymphoma kinase (ALK)-resistant NSCLC cells and synergistic effects in combination with alectinib in alectinib sensitive cells.
  • Alectinib is the active ingredient in AlecensaTM, an ALK inhibitor approved for the treatment of NSCLC.
  • Moreover, effective inhibition of signaling pathways associated with osimertinib and alectinib resistance were observed in the respective cell lines tested.

Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting

Retrieved on: 
일요일, 4월 7, 2024
Diamond, EGFR, Helmy Eltoukhy, Mutation, Prevalence, NSCLC, Survival, Foundation Medicine, Patient, Cancer, Lung cancer, AACR, PACC, TKI, Drug resistance, MD Anderson Cancer Center, Associate professor

CAMBRIDGE, Mass., April 07, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, presented real-world evidence of the evolving epidermal growth factor receptor (EGFR) mutation landscape in non-small cell lung cancer (NSCLC), and the potential of BDTX-1535 to address a broader range of mutations compared to existing therapies. The results were disclosed in an oral presentation on April 7, 2024, at the 2024 American Association of Cancer Research (AACR) Annual Meeting held in San Diego, California.

Key Points: 
  • The results were disclosed in an oral presentation on April 7, 2024, at the 2024 American Association of Cancer Research (AACR) Annual Meeting held in San Diego, California.
  • The analyses reveal a broad spectrum of non-classical mutations, as well as an increased prevalence of the acquired resistance mutation, C797S.
  • The compound also potently inhibits the drug resistance C797S mutation, which emerges following treatment with third-generation EGFR inhibitors, including osimertinib.
  • Black Diamond is currently advancing BDTX-1535 in a Phase 2 trial for patients with EGFRm NSCLC across multiple lines of therapy.

HiberCell Announces Recent Publication and Poster Presentations for its Novel GCN2 Activator, HC-7366

Retrieved on: 
금요일, 4월 5, 2024
SOC, EGFR, GCN2, NSCLC, Journal, Abstract, AACR, Publication, Therapy, Metastasis, Medicinal chemistry, Pharmaceutical industry

This publication and abstracts are now available online and on the AACR website, respectively.

Key Points: 
  • This publication and abstracts are now available online and on the AACR website, respectively.
  • Our first poster features the remarkable preclinical activity of HC-7366 as monotherapy and in combination with belzutifan in clear cell renal cell carcinoma models (ccRCC).
  • This work was foundational to our ongoing Phase 1b study in ccRCC in combination with belzutifan, which was announced earlier this year.
  • Abstract Title: HC-7366, a potent GCN2 kinase activator, augments osimertinib therapy to delay resistance in EGFR mutant NSCLC models.

FibroBiologics Presents Data from Dermal Fibroblast Spheroid-based Treatment of Chronic Wounds in a Diabetes Mouse Model at Advanced Wound Care Summit USA

Retrieved on: 
목요일, 4월 4, 2024
Diabetes, Fibroblast, EGFR, Warfarin necrosis, Risk, Communication, IL-6, Form, Diabetic foot ulcer, Conditional sentence, Patient, Research, Mouse, Gamma ray, Trial of the century, HDF, Hyperglycemia, Acceleration, Wound healing, Cytokine, Therapy, Cellular senescence, Interleukin, VEGF, Pharmaceutical industry

These findings will be presented via an oral and poster presentation at the Advanced Wound Care Summit USA in Boston, MA, April 16-17.

Key Points: 
  • These findings will be presented via an oral and poster presentation at the Advanced Wound Care Summit USA in Boston, MA, April 16-17.
  • Diabetic foot ulcers (DFUs) are prevalent in individuals with diabetes, with approximately 33 million people impacted globally.
  • FibroBiologics' research aims to address this issue by investigating the potential of using human dermal fibroblast (HDF) spheroids in promoting and accelerating the wound healing process in diabetic patients.
  • "These results support the potential of HDF spheroids to expedite the healing process of chronic wounds associated with diabetes," said Dr. Khoja.

QIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Annual Meeting 2024

Retrieved on: 
수요일, 4월 3, 2024
EGFR, Gene, Nested polymerase chain reaction, Professor, Cancer Institute, Circulating free DNA, Neoplasm, TCR, Research institute, QGEN, Research, PCR, Central business district, NGS, DNA, BRAF, Diagnosis, WIA, Cancer, Immune system, Liquid biopsy, UMI, Mutation, Genetics, Human genetics, Senior, AACR, Medical school, QIAGEN, Poster, Environment, IVD, Urine

Two Exhibitor Spotlight Theater sessions and several poster presentations will highlight additional advances from QIAGEN in this field.

Key Points: 
  • Two Exhibitor Spotlight Theater sessions and several poster presentations will highlight additional advances from QIAGEN in this field.
  • EGFR and BRAF are genes essential for normal cell growth and function, but mutations in these genes can result in cancer development.
  • To advance research on how the immune system interacts with cancer, QIAGEN has introduced the QIAseq Targeted RNA-seq Panel for T-cell receptors.
  • Learn more about QIAGEN’s offering at the AACR Annual Meeting 2024, (booth #922 in the San Diego Convention Center) and poster presentations highlighting new solutions in digital PCR, NGS and preanalytical workflows at https://www.qiagen.com/applications/cancer-research/aacr-2024-annual-mee... .

Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update

Retrieved on: 
금요일, 3월 29, 2024
Multiple myeloma, Private placement, Symantec Endpoint Protection, EGFR, CD8, Exercise, Disease, AML, HNSCC, CMV, Patient, Common, Tom Clancy's Ghost Recon, Neoplasm, Immunoglobulin A, Tumor microenvironment, Sale, Bristol Myers Squibb, Form 10-K, Cancer, MHC, PD-L1, Antibody, Interim, Therapy, MTD, Poster, Total, ETB, UPR, Pharmaceutical industry

The net loss attributable to common shareholders for the fourth quarter of 2023 was $3.9 million, or $0.73 per basic and diluted share.

Key Points: 
  • The net loss attributable to common shareholders for the fourth quarter of 2023 was $3.9 million, or $0.73 per basic and diluted share.
  • Revenues for the fourth quarter of 2023 were $7.0 million, compared to $2.6 million for the same period in 2022.
  • Revenues for the fourth quarter of 2023 were comprised of revenues from collaborative research and development agreements with Bristol-Myers Squibb and grant revenue.
  • For more details on MTEM’s financial results for 2023, refer to Form 10-K filed with the SEC.

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

Retrieved on: 
목요일, 3월 28, 2024
Research, JDRF, Kidney disease, Massachusetts General Hospital, Risk, Immunosuppression, Patient, Kidney transplantation, OLE, University, Tacrolimus, Glomerular filtration rate, Net, Investment, Society, Hospital, EGFR, Kidney, Safety, Pharmacokinetics, FACS, Annual general meeting, Pharmaceutical industry

IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its fourth quarter and full year 2023 operating and financial results and reviewed recent business highlights.

Key Points: 
  • In addition to our clinical development progress, tegoprubart was used for immunosuppression in historical kidney and heart pig-to-human xenotransplant procedures.
  • The procedure was completed on March 16, 2024, at Massachusetts General Hospital on a 62-year-old man with end-stage kidney disease.
  • Results were presented at the American Society of Nephrology Kidney Week 2023 Annual Meeting held in Philadelphia, PA in November 2023.
  • General and administrative expenses were $12.7 million for the year ended December 31, 2023, compared to $12.7 million for the year ended December 31, 2022.

ArriVent BioPharma Reports Full Year 2023 Financial Results

Retrieved on: 
목요일, 3월 28, 2024
Research, EGFR, Conference, Breakthrough therapy, NSCLC, Patient, Food and Drug Administration, Lung cancer, Therapy, PACC, Safety, ADC, FDA, SHP2, Food, Pharmaceutical industry

In September 2023, ArriVent and its partner, Shanghai Allist Pharmaceuticals Company, Ltd. ("Allist”), presented interim Phase 1b results at the World Conference on Lung Cancer.

Key Points: 
  • In September 2023, ArriVent and its partner, Shanghai Allist Pharmaceuticals Company, Ltd. ("Allist”), presented interim Phase 1b results at the World Conference on Lung Cancer.
  • In January 2024, ArriVent appointed Winston Kung as Chief Financial Officer and Treasurer, bringing over 20 years of extensive leadership experience, most recently as Chief Financial Officer and Chief Operating Officer at PMV Pharmaceuticals.
  • Research and development expenses were $64.9 million and $30.4 million for the years ended December 31, 2023 and 2022, respectively.
  • Net loss was $69.3 million and $37.0 million for the years ended December 31, 2023 and 2022, respectively.

Affimed Reports 2023 Financial Results and Operational Progress

Retrieved on: 
목요일, 3월 28, 2024
Research, EGFR, GVHD, NSCLC, Genentech, ASH, AML, PD, Disease, International, International Financial Reporting Standards, Patient, Webcast, EFS, EDT, CRS, Cancer, Record, Insurance, Trial of the century, Bank statement, Investment, Safety, Workforce, Roivant Sciences, PFS, IASB, Hodgkin lymphoma, Book, NK, HL, Cytokine release syndrome

MANNHEIM, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results and provided an update on clinical and corporate progress for the year ended December 31, 2023.

Key Points: 
  • MANNHEIM, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results and provided an update on clinical and corporate progress for the year ended December 31, 2023.
  • Based on the promising results, Affimed expanded enrollment in this cohort to 40 patients.
  • Affimed prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by the IASB.
  • Affimed will host a conference call and webcast on March 28, 2024, at 8:30 a.m. EDT / 13:30 CET to discuss full year 2023 financial results and corporate developments.